Tandem Diabetes annual meeting results: all director nominees elected, 2023 LTIP approved

TANDEM DIABETES CARE INC

Stockholders elected 7 directors; Blickenstaff, Cha, Howell, Malagueira, McGroddy-Goetz, Sheridan, Twomey.
2023 Long-Term Incentive Plan approved with 51.8M votes for, 4.1M against.
Named executive officer compensation approved on advisory basis (45.7M for, 10.3M against).
Ernst & Young ratified as auditor for FY2023 (58.1M for, 0.8M against).
Deadline for Rule 14a-8 proposals for 2024 annual meeting: December 14, 2023.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

TANDEM DIABETES CARE INC shareholders approved To ratify of the appointment of Ernst & Young LLP to serve as the Company's independent registered public accountant for the year ending December 31, 2023. at the 2023-05-24 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-05-24

Exact text from the filing

Proposal 4 : To ratify of the appointment of Ernst & Young LLP to serve as the Company's independent registered public accountant for the year ending December 31, 2023. The proposal received the following votes: For Against Abstain Broker Non-Votes 58,058,014 790,996 65,483

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

TANDEM DIABETES CARE INC shareholders approved To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. at the 2023-05-24 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-05-24

Exact text from the filing

Proposal 3 : To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. The proposal received the following votes: For Against Abstain Broker Non-Votes 45,684,932 10,258,454 50,633 2,920,474

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

TANDEM DIABETES CARE INC shareholders approved To approve the Company's 2023 Long-Term Incentive Plan, which will replace the 2013 Stock Incentive Plan expiring on November 15, 2023. at the 2023-05-24 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2023-05-24

Exact text from the filing

Proposal 2 : To approve the Company's 2023 Long-Term Incentive Plan, which will replace the 2013 Stock Incentive Plan expiring on November 15, 2023. The proposal received the following votes: For Against Abstain Broker Non-Votes 51,791,463 4,104,680 97,876 2,920,474

View on SEC.gov

Browse all shareholder votes →

TANDEM DIABETES CARE INC filing history →

Source: SEC EDGAR

accession 0001438133-23-000094

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.